Saudi Arabia Breast Cancer Therapeutics Market Report 2022 to 2030

Saudi Arabia Breast Cancer Therapeutics Market Analysis

$ 3999

The increasing awareness about breast cancer and its advanced treatment options is leading to Saudi Arabia's breast cancer therapeutics market growth from $309 Mn in 2022 to $908 Mn in 2030 with a CAGR of 14.4% for the year 2022-30. The market is segmented by therapy, by cancer type, and by distribution channel. Hikma, Abbvie, and Amgen are some of the major market players in the Saudi Arabia breast cancer therapeutics market.

ID: IN10SAPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: Saudi Arabia AUTHOR: Parul Choudhary

Buy Now

Saudi Arabia Breast Cancer Therapeutics Market Executive Analysis

Saudi Arabia's breast cancer therapeutics market size is at around $309 Mn in 2022 and is projected to reach $908 Mn in 2030, exhibiting a CAGR of 14.4% during the forecast period. Saudi Arabia would spend $36.8 Bn or 14.4% of its 2022 budget on healthcare and social development 2022. Saudi Arabia aims to privatize 290 hospitals and 2,300 primary health centers by 2030, investing $66.67 Bn in healthcare infrastructure and increasing private sector participation from the current 40% to 65%. Increased investment in infrastructure and innovation is anticipated to spur significant growth in the Saudi Arabian healthcare industry as the country's population is expected to increase from $34.3 Mn in 2019 to $39.4 Mn by 2030 and the country's life expectancy to rise from 76.4 to 81.8 years by 2050.

In Saudi Arabia, breast cancer is the most prevalent type of cancer that affects women. The incidence and death age-standardized rates (ASR) for Saudi women in 2018 were 27.3 and 7.5, respectively. Primary healthcare facilities in Saudi Arabia engage with patients and offer free public healthcare. Unfortunately, a number of women forgo early detection and therapy options due to a lack of information, awareness, and recognition of breast cancer as well as general screening practices in Saudi Arabia. Depending on a number of variables, including genetic mutation, cancer stage, and metastatic status, adjuvant treatment options for breast cancer include radiotherapy, chemotherapy, surgery, and hormone therapy. Progesterone receptor-positive ("PR-positive") and oestrogen receptor-positive ("ER-positive") patients account for about three-quarters of all breast cancer patients; as a result, the majority of patients receive hormonal therapy for five to ten years. Lower rates of disease recurrence, metastasis, death, and disease-free survival are linked to the favorable effects of hormonal therapy. Given the relatively long period of hormone therapy, compliance with the medication is a clinically important concern. To get the optimum outcomes, patients must take hormone therapy daily for five to ten years.

saudi arabia breast cancer therapeutics market analysis

Market Dynamics

Market Growth Drivers

The expansion of the Saudi Arabia breast cancer therapeutics market is anticipated to be boosted by the rise in breast cancer awareness and the rise in healthcare spending in Saudi Arabia. Major companies are involved in the development of therapeutics for breast cancer, and it is anticipated that the launch of new drugs would significantly affect the breast cancer therapeutics market in Saudi Arabia.

Market Restraints

Saudi Arabia's breast cancer therapeutics market growth is hampered by the high development costs for new drugs, the risk of failure, and the undesirable side effects of breast cancer therapeutics.

Competitive Landscape

Key Players

Tabuk (SAU)
Spimaco (SAU)
Hikma (SAU)
Abbvie
Amgen
Astellas
AstraZeneca
Bristol-Myers Squibb

Healthcare Policies and Regulatory Landscape

Through the Ministry of Health and the National Health Insurance Company (NHIC), the Saudi Arabian government does offer all of its residents' access to universal health care. Access to medical care, including breast cancer treatment, in government-funded hospitals and clinics, is included in this coverage. For people covered by the national health insurance scheme, the NHIC is in charge of medical reimbursements.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Saudi Arabia Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.